<DOC>
	<DOCNO>NCT00346359</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy , fludarabine busulfan , donor peripheral stem cell transplant help stop growth abnormal cancer cell . It also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune system help destroy remain abnormal cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving antithymocyte globulin , tacrolimus , methotrexate transplant may stop happen . PURPOSE : This phase II trial study well give fludarabine together busulfan follow donor peripheral stem cell transplant antithymocyte globulin , tacrolimus , methotrexate work treat patient myeloid cancer .</brief_summary>
	<brief_title>Fludarabine Busulfan Followed Donor Peripheral Stem Cell Transplant Antithymocyte Globulin , Tacrolimus , Methotrexate Treating Patients With Myeloid Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine incidence severity acute graft-versus-host disease ( GVHD ) patient myeloid malignancy treat condition regimen comprise fludarabine phosphate busulfan follow allogeneic peripheral blood stem cell transplantation GVHD prophylaxis comprise antithymocyte globulin , tacrolimus , methotrexate . - Determine incidence donor engraftment patient treat regimen . Secondary - Determine pharmacokinetics IV busulfan , include interdose variability evaluation limit sample strategy , patient . - Determine pharmacokinetics antithymocyte globulin patient . - Determine pharmacokinetics fludarabine phosphate effect lymphocytes patient . - Determine incidence specific toxic effect ≥ grade 3 patient treated regimen . - Determine incidence severity chronic GVHD patient . - Determine incidence nonrelapsing mortality 100 day 1 year transplantation patient . - Determine incidence relapse patient . - Determine relapse-free survival patient . - Determine incidence Epstein-Barr virus activation patient . OUTLINE : - Conditioning regimen : Patients receive fludarabine phosphate IV 30 minute day -6 -2 busulfan IV 3 hour day -5 -2 . Prior condition regimen , patient whose cerebrospinal fluid positive malignant cell receive intrathecal methotrexate cranial irradiation CNS prophylaxis . - Allogeneic peripheral blood stem cell ( PBSC ) transplantation : Patients receive filgrastim ( G-CSF ) -mobilized allogeneic PBSCs IV day 0 . - Graft-versus-host disease prophylaxis : Patients receive antithymocyte globulin IV least 10 hour day -3 -1 . They also receive tacrolimus orally twice daily IV continuously begin day -1 continue day 55 , follow taper day 180 absence graft-versus-host disease . Patients also receive methotrexate IV day 1 , 3 , 6 , 11 . After completion study treatment , patient follow annually . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 follow myeloid malignancy : Chronic myelogenous leukemia meeting 1 follow criterion : Chronic phase Accelerated phase Treated blast phase Acute myeloid leukemia meet 1 follow criterion : In remission In early relapse , define &lt; 10 % marrow blast Myelodysplastic syndrome , include risk group Other myeloproliferative disorder HLAA , B , C , DRB1 , DQB1 match related unrelated donor available PATIENT CHARACTERISTICS : No disease would severely limit life expectancy AST ≤ 2 time normal Creatinine ≤ 2 time normal OR creatinine clearance ≥ 60 mL/min No cardiac insufficiency require treatment No symptomatic coronary artery disease PO_2 ≥ 70 mm Hg AND DLCO ≥ 70 % predict OR PO _2 ≥ 80 mm Hg AND DLCO ≥ 60 % predict HIV negative Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : No posttransplantation growth factor methotrexate administration</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>graft versus host disease</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>juvenile myelomonocytic leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>chronic idiopathic myelofibrosis</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>